Malaria remains the world's most prevalent human parasitic disease. Because of the rapid spread of drug resistance in parasites, there is an urgent need to identify diverse new drug targets. One group of proteases that are emerging as targets for novel antimalarials are the metalloaminopeptidases. These enzymes catalyze the removal of the N-terminal amino acids from proteins and peptides. Given the restricted specificities of each of these enzymes for different N-terminal amino acids, it is thought that they act in concert to facilitate protein turnover. Here we review recent structure and functional data relating to the development of the Plasmodium falciparum metalloaminopeptidases as drug targets Addresses
Introduction
The metalloaminopeptidases (MAPs) constitute a diverse set of protease enzymes with essential roles in cell maintenance, growth and development, and defense. Their active sites coordinate essential metal ion(s) that activate a water molecule to form an hydroxide nucleophile which attacks the scissile peptide bond, releasing the P1 position amino acid 1 [1] . The aminopeptidases are classified into families based on structural patterns and substrate specificity in particular by the preference shown for specific amino acids at the P1 position [2] .
Parasites of the genus Plasmodium are the causative agents of malaria. While four Plasmodium species commonly infect humans, Plasmodium falciparum (Pf) causes the most deaths [3] [4] [5] . To date, nine MAPs have been identified in Pf (3D7) [6] . Four of these are methionine aminopeptidases. The other five enzymes comprise a prolyl iminopeptidase (or post-prolyl aminopeptidase), 2 a prolyl aminopeptidase (see footnote 2), a leucine aminopeptidase, an alanine aminopeptidase and an aspartyl aminopeptidase. Given the restricted specificities of each of these enzymes for particular N-terminal amino acids, it is thought that they act in concert to facilitate hemoglobin (Hb) catabolism [7, 8] , a process essential to the survival of Pf. However, recent studies show that the PfMAPs may have additional roles to that of Hb digestion, including important housekeeping functions and in conjunction with the parasite proteosome [9 ,10] . The essential nature of the PfMAP activity has sparked interest in using them as targets for the development of novel antimalarials [11, 12] .
Drug campaigns have successfully targeted proteases; for example, the angiotensin-converting enzymes (hypotension drugs including the original Captopril, Bristol Myers Squibb) and HIV protease (HIV/AIDs anti-retrovirals including the original Saquinavir, Hoffman-La Roche). However, developing drugs for new protease targets has proven to be particularly challenging, in part due to the importance of achieving selectivity [13] . Since the parasite and host MAPs show limited sequence identity (<35%) and have differing substrate specificities, rational design and delivery of selective parasite-specific inhibitors is an exciting possibility. A general approach for therapeutically targeting proteases is to identify specific inhibitors -generally small molecules -that can block the active site. The search for inhibitors can be accelerated with knowledge of both the active site structure and the intrinsic subsite occupancy. If rational drug design platforms are going to succeed, it will be absolutely essential that precise structure-activity-relationship and mechanistic data are available that can be used to exploit selective intricacies of the parasite enzyme over its mammalian homologs.
The methionine aminopeptidases
The methionine aminopeptidases (MetAP) perform the essential housekeeping role of catalyzing the removal of 1 The nomenclature of Schechter and Berger [1] is used here. P1 and P1 0 refer to substrate residues while the S1, S1 0 refer to the corresponding enzyme subsites.
the N-terminal initiator methionine during protein synthesis [14] . Two distinct types of MetAP enzymes exist, MetAP1 and MetAP2, having mutually redundant yet essential functions within all organisms [15] . In comparison to MetAP1, MetAP2 has a 65 amino acid insertion in its catalytic domain and an additional N-terminal domain (in eukaryotes) [14] . The PfMetAP2 enzyme contains a 274 residue N-terminal domain and a conserved catalytic C-terminal domain [16] (Figure 1a) . Recombinant PfMetAP2 binds fumagillin derivatives with high selectivity and these compounds are now being considered as antimalarial agents targeting PfMetAP2 [16] .
There are three isoforms of MetAP1 in Pf; PfMetAP1a, PfMetAP1b and PfMetAP1c [6] (Figure 1a) . The three MetAP1 isoforms are active and have comparable activities to other members of the mammalian MetAP1 family [17] . PfMetAP1a contains the minimal catalytic domain and PfMetAP1c has a signal peptide in its longer Nterminal for targeting the enzyme to the apicoplast [16] ( Figure 1a) . PfMetAP1b is the most characterized of the three MetAP1s. It is expressed in the early intra-erythrocytic stage of the Pf lifecycle [18] . Inhibition of PfMetAP1b with the highly selective compound XC11 that contains a 2-(2-pyridinyl)-pyrimidine core resulted in inhibition of Pf proliferation in vitro and was active in mouse malaria models that included drug-resistant Pf strains [17] . It has been suggested that PfMetAP1b is a promising target for the development of novel antimalarial drugs [17] . There are currently no published structures of the PfMetAPs; however, the Structural Genomics Consortium solved the structure of PfMetAP1b, the target of the antimalarial XC11 compound (3S6B, deposited RCSB 2011). The structure shows a typical MetAP1 core fold of pseudo twofold-related N-terminal and Cterminal domains, containing two a-helices and two antiparallel b-strands (Figure 1b) . Unlike characterized mammalian homologs, the PfMetAP1b active site contains a single FeIII ion rather than a di-metal core. The biological relevance of this difference remains unknown. Structural alignment of 3S6B with other known MetAP1 folds identifies the human MetAP1b as the closest structural homolog (and 4FLI the closest structural homolog) [19] . Structural alignment of the human enzyme with PfMetAP1b identifies that the FeIII ion in PfMetAP1b is equivalent to one metal ion site present in the human MetAP1 structures and that a water molecule occupies the second metal site (Figure 1b) .
The PfA-M1 alanyl aminopeptidase enzyme is responsible for the final stages of hemoglobin (Hb) digestion [9 ] , a process that provides a source of amino acids for incorporation into parasite proteins [20] [21] [22] . The PfA-M1 enzyme has a broad specificity for the P1 amino acid and includes most basic and hydrophobic amino acids [23, 24, 25 ] but preferentially cleaves leucine and methionine [25 ] . PfA-M1 also has subsite specificity requirements for activity [26 ] . Engagement of the S1, S1
0 and S2 0 subsites can contribute to the catalytic efficiency [26 ] . Proteolytic activity of PfA-M1 has been identified in both the parasitic cytosol and the digestive vacuole, the membrane vesicle where Hb digestion begins [7, 9 ,23,24,27]. Whether PfA-M1 digests Hb peptides in the digestive vacuole or the cell cytosol has been the topic of debate [7,9 ,23,24,27-29,30 ]. The PfA-M1 enzyme shows a 100-fold decrease (k cat /K m ) in overall efficiency in an acidic
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The structure of the PfMetAPs. (a) The domain structure of the PfMetAPs. The three isoforms of PfMetAP1 all contain a canonical MetAP1 catalytic domain (shown in ruby). PfMetAP1c contains an Nterminal signal peptide (in blue, SP) followed by a transit peptide domain (in green, T) to target the enzyme to the apicoplast [16] . PfMetAP1c also contains a 210 residue insertion in the MetAP1 catalytic domain (shown as black line). The PfMetAP2 enzyme has a 274 residue Nterminal extension (in green, NTE) before a canonical MetAP2 domain. (b) The 1.95 Å X-ray crystal structure of PfMetAP1b shows a canonical MetAP1 fold (in ruby) (3S6B, MolProbity Quality Score 1.42 = 97th percentile). The PfMetAP1b enzyme has an N-terminal extension of 56 amino acids when compared to the human enzyme representatives (in gray in a and b), extra 10 unstructured amino acids at its C-terminus (in gray). A single FeIII ion (orange sphere) is coordinated by residues H270, E303 and E334 (shown in sticks). A water molecule (light blue sphere) is located in the second metal site in other MetAP1 structures and is coordinated by conserved active site residues D193 and D204 (shown in sticks). The water molecule contributes to an apparent pentavalent coordination of the FeIII ion (metal bonds shown as black dashes).
pH (representing the digestive vacuole environment), arguing for a cytosolic function [23, 24, 29, 31] . However, specific inhibition of the enzyme results in a change in the digestive vacuole morphology [9 ] and Ragheb et al.
[30 ] convincingly argue that, although the enzyme is less efficient at the vacuole pH (acidic), the high concentration of Hb peptide substrates (low mM in the vacuole) drives the substrate binding to PfA-M1 and leads to sufficient aminopeptidase activity [30 ] .
PfA [9 ,24,35,36 ] , and hydroxamate derivatives [37, 38 ] .
830 Catalysis and regulation The X-ray crystal structure of PfA-M1 (a) and PfA-M17 (b) and examples of recent dual inhibitors of the two enzymes. PfA-M1 (a) adopts a canonical bacterial aminopeptidase fold and is divided into four domains (cartoon is colored by domain). A simplified domain architecture with residue numbers of domain boundaries is shown underneath cartoon model. The active site is located in domain II and is completely buried within the protein's core (domain II in green). The active site (inset) contains a single catalytic zinc ion (shown as black sphere, inset a) and is coordinated by a classic catalytic triad of H496, H500, E519 (shown in sticks, inset a) and a water molecule (in yellow) in its unbound form. Short molecular dynamic simulations of the PfA-M1 (75 ns of apo-bound and inhibitor-bound enzyme) [50] suggest the enzyme uses a two-step catalytic mechanism, in which the conformation of the active site is altered between the Michaelis complex and the transition state [50] . PfA-M17 is a biological homohexamer and is shown as a cartoon model (b). Each PfA-M17 monomer contains an N-terminal regulatory domain (N-terminal domain shown in green) and a C-terminal catalytic domain (shown in red, Figure 4a ) that together adopt the leucine aminopeptidase (LAP) family fold [51] . A helical linker connects the N-terminal and C-terminal (shown in yellow). A simplified domain architecture with residue numbers of domain boundaries is shown underneath cartoon model. The active site of M17 contains two metal-binding sites (inset b), a readily exchangeable site (site 1) and a tight binding site (site 2) [44 ,45] . The LAP enzyme family members also have a well-coordinated carbonate ion in their active site (shown as sticks, inset b). The metal ions are coordinated by residues K374, D379, D399, D459 and E461 (shown as sticks, inset b). The divalent metal cation binding at site 1 of PfA-M17 can be functionally exchanged for other metal cations, the enzyme displaying a preference in the order Zn 2+ > Mn 2+ > Co 2+ > Mg 2+ [45] . The type of metal cation in the active site of these enzymes can therefore influence the catalytic efficiency against peptide substrates as well as the binding of inhibitors. The X-ray crystal structures of PfA-M1 and PfA-M17 have both been solved in their bound and unbound states. Two potent inhibitors of the enzymes, Bestatin and hPheP[CH2]Phe, have been structurally analyzed when bound to both PfA-M1 and PfA-M17 [24, 44 ] . The two inhibitors, CHR-2863 and BDM14471, have both shown antiplasmodial activity against drug resistance strains of malaria [38 ,40 ] .
The active site of PfA-M1 contains a single catalytic zinc ion (Figure 2) . The inhibitor scaffolds all act to chelate the zinc ion and mimic the transition state of the molecule. Targeting the zinc ion using phosphonopeptides and bestatin derivatives produced potent inhibitors of the enzyme [9 ,24,32,33,36 ] ; however, creating a parasite specific inhibitor is likely to require the engagement of specific elements of the PfA-M1 architecture. Like many proteases, PfA-M1 has an ability to accommodate organic molecules even when its active site is buried within a large protein. Velmouragane et al. showed that the S1 pocket is capable of substantial inhibitor-induced rearrangement due to the presence of a flexible polar glutamic acid (Glu572) in the pocket [36 ] . One of the best cleaved P1 residues is Arg or homoArg [25 ] and recent work has shown that derivatives of these amino acids are also able to induce changes in the backbone position of S1 pocket that are not associated with Glu572 [39] .
The cellular location of the PfA-M1 enzyme also represents significant challenges for drug design and delivery; however, recent advances show that compounds can be delivered and reach the site of action. An orally bioavailable hydroxamate-containing ester, CHR-2863, has been shown to be efficacious against murine malaria (Plasmodium chaubaudi) [40 ] . The compound is, however, a close relative of Tosedostat, a potent inhibitor of a number of intracellular mammalian aminopeptidases. The authors conclude that CHR-2863 still requires toxicity testing but represents an important step forward in showing that the PfMAPs can be targeted by oral administration of inhibitors [40 ] . In a separate study, a malono-hydroxamic lead compound [37] , with good physicochemical properties, in vitro plasma stability and promising antiplasmodial activity in vitro, was assessed in mice using the malaria strain Plasmodium berghei [38 ] . The in vivo results did not match the potency noted in vitro and Deprez-Poulain et al., then assessed the plasma concentration and distribution of BDM14471 after a single dose in mice [38 ] . The results showed that the compound was capable of penetrating the erythrocyte, indicating that this was not the cause of the gap between the in vitro and in vivo results. The authors suggested, given these results that the proteolytic activity of PfA-M1 is not critical for survival of intra-erythrocytic parasites, but does concede that the compound may be trapped in the red blood cell and not actually enter the parasite [38 ] . A further question, not highlighted in the article, is whether the compound can penetrate the digestive vacuole where the proteolytic activity of PfA-M1 is thought to predominate [9 ] .
The leucyl aminopeptidase, PfA-M17
The leucyl Aminopeptidase PfA-M17 is postulated to be involved in the Hb digestion pathway, generating free amino acids at the final stages of this process [41] . However, in contrast to PfA-M1, PfA-M17 may have additional function(s) since specific inhibition of its activity in Pf parasite cultures causes growth retardation early in the intra-erythrocytic life cycle before Hb digestion is initiated [8, 9 ] .
PfA-M17 possesses a severely restricted specificity for Nterminally exposed bulky, hydrophobic amino acids [25 ] and a preference for leucine [41] . A similar substrate and biochemical profile was obtained when the M17 aminopeptidase from Plasmodium vivax was characterized [42] . A possible explanation for the essential role of the PfA-M17 (and indeed PfA-M1) is that, in addition to regulating the general intracellular pool of amino acids, both PfA-M1 and PfA-M17 are critical in the hydrolysis of dipeptides that release free leucine. The only amino acid
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The X-ray crystal structure of PfM18AAP reveals a dodecameric assembly. The model of PfM18AAP is shown as a space-filled molecule, except for chain A which is shown as cartoon. The molecule is colored by chain and not all 12 chains are visible in this view. Each PfM18AAP monomer (chain A is shown as cartoon to show detail of monomer) contains two domains -one predominantly used for protein-protein interactions (in cyan, regulatory domain) and a second catalytic domain (in magenta, Figure 4 ). Together the two domains adopt a typical aspartyl aminopeptidase fold [46 ] . A simplified domain architecture with residue numbers of domain boundaries is shown underneath cartoon model. Three PfM18AAP catalytic domains interact to form a cone-shaped trimer and regulatory domains act as packing buffers between the trimer of catalytic domains. The dodecameric enzyme is built from the interactions of four PfM18AAP trimers with an interior active site cavity of M18 comprising four trimer cones, each with their three active sites [46 ] . The active site of PfM18AAP also has a di-cation core as shown in the inset (zinc ions shown as black spheres) and the metals are coordinated by residues H87, D325, E381, D435 and H535 (shown as sticks, inset).
not found in human Hb and which cannot be synthesized by the parasite is isoleucine. This amino acid must be obtained from the external environment [20] . The uptake of isoleucine by parasites is mediated by a two-step process involving an ATP-independent transported capable of exchanging intra-cellular leucine for isoleucine, and the ATP-dependent storage or accumulation of this amino acid within parasites [43] .
The PfA-M17 enzyme forms a functional homohexamer [41, 44 ]. The X-ray crystal structure of the M17 revealed the complex detail of the biological hexamer (Figure 3 ) [44 ] . PfA-M17 uses self-association to restrict access to its active sites and as such proteolysis is subject to spatial and temporal control. Access to the enclosed active-site cavity has been hypothesized to occur via channels formed by the N-terminal domains of each monomer [44 ] . Each PfA-M17 active site contains two metalbinding sites, a readily exchangeable site (site 1) and a tight binding site (site 2) [45] . While M17 retains residual catalytic activity when the metal ion from site 1 is removed, the removal of metal ions from both sites results in an inactive apo-enzyme that cannot be re-activated by addition of divalent metal cations [45] .
The aspartyl aminopeptidase, PfM18AAP
Despite annotation as an aspartyl aminopeptidase, the PfM18AAP enzyme has highly restricted specificity for glutamate as well as aspartate [46 ,47] and reduced activity against asparagine [46 ] . The precise role of PfM18AAP in Pf remains unknown and will require potent and specific inhibitors/activity-based probes to identify its function in vivo. Gene disruption/truncation experiments of PfM18AAP indicated that the enzyme was dispensable for blood-stage replication but had an associated fitness cost to the parasite [7] . Anti-sense RNA knockdown of PfM18AAP, however, resulted in parasite growth abnormalities, vascularization, and cellular damage [47] . The 
PfA-M1(DV)
The current status of the role of the PfMAPs in the intra-erythrocytic parasites. All three PfMetAP1 isoforms are detectable in the early erythrocytic lifecycle; however, microarray analysis indicates that PfMetAP2 is not expressed in this stage. PfMetAP1a has continual expression throughout this stage of the lifecycle. The role of the PfMetAP1a-c is thought to be in protein synthesis, removing the initiator methionine from newly synthesized proteins. The X-ray crystal structure of PfMetAP1b is depicted in ruby. The location of the enzyme is generally considered to be close to the ribosome (depicted in gray, Rb) that can be found associated with the endoplasmic reticulum (orange) or free in the cytosol. mRNA (shown in gray) leaving the nucleus (blue) is translated to produce an amino acid peptide chain (depicted as yellow beads) that will fold into an active protein. The role of the nuclear PfA-M1 is currently unknown. The remaining PfMAPs are thought to be involved in Hb digestion. Hb is transported into the parasite from the red blood cell (RBC) through vesicles. The Hb molecule is delivered to a specialized food vacuole or digestive vacuole (DV). Once internalized, a proteolytic cascade occurs incorporating numerous proteases of various mechanistic classes. Once the Hb is broken down to smaller peptides (typically 2-8 amino acids in length, depicted as red 'beads on a string'), the PfMAPs take over the final digestion to produce free amino acids. PfA-M1 is functional in both the DV and the cytosol although evidence would suggest that its primary role is inside the DV. PfA-M17 and PfM18AAP (colored by chain) are cytosolic and thought to contribute to Hb digestion, in addition to putative other roles in the Pf lifecycle. The specificity of each PfMAP is shown by single letter amino acid codes (shown inside black circles). The preference for each amino acid is shown in descending order.
cellular localization and role in growth and development suggest that, like PfA-M17, PfM18AAP may also have important functions in addition to Hb digestion [10, 47] .
The biological assembly of the PfM18AAP is a dodecamer that forms a tetrahedron shape (Figure 3 ) in a similar arrangement to the M42 glutamyl aminopeptidases [48] . PfM18AAP shares only 34% identity with the human enzyme and contains a large insertion of 65 amino in the regulatory domain that is unique to the Pf enzyme (it is not present in other Plasmodium M18 enzymes that share > 75% identity). The role of this unique insertion remains unknown [10,46 ,47] . The location of this loop indicates that it may act as a sentinel, guarding the pore entry to the inner active site cavity (Figure 3) . PfM18AAP thus resembles a proteasomal-like machine with multiple active sites able to degrade peptide substrates that enter the central lumen [46 ] . Each active site contains two well-coordinated zinc ions [46 ] . The active site of each monomer is a small closed cavity that has a small entrance (diameter 5.6 Å ) [46 ] . Studies using chelation agents have shown that altering the type of metal ion can increase catalytic efficiency but does not affect binding of the substrate [47] . To date, no potent inhibitors of PfM18AAP have been published; however, a highthroughput screening approach has been undertaken and results of this bioassay are publically available from the PubChem BioAssay.
Conclusions and outlook
The artemisinin-based combination therapies (ACTs) are the current regime for malaria and have been deployed globally with tremendous success for over a decade. Recent reports, however, of the emergence of resistance to the artemisinins in South-East Asia is alarming. Should the ACTs fail, no suitable first-line treatments are available for Pf malaria [49] . The PfMAPs have essential biological functions in Pf (Figure 4 ) and represent attractive targets for the development of novel antimalarial agents. Similarities between different classes of enzyme raise the possibility of designing combination inhibitors -one compound to target one or more PfMAPs, thus slowing the emergence of drug resistant parasites. The PfA-M1 and PfA-M17 enzymes show promise in this regard. To overcome the many challenges of producing drugs against the PfMAPs, a simultaneous dual approach will be necessary. Our understanding of the biological role that the enzymes fulfill within the parasite lifecycle is absolutely pivotal to success as are the initial compound discovery campaigns to identify, test, optimize and develop potent inhibitors that can be used in downstream drug development. Fingerprinting the substrate specificity of M1 and M17 neutral aminopeptidases of human malaria, Plasmodium falciparum. PLoS ONE 2012, 2:e31938. This paper defines the substrate specificity of PfA-M1 and PfA-M17 by screening in vitro proteolytic activity against a library of 61 fluorogenic substrates derived from natural and non-natural amino acids. A detailed substrate fingerprint for each protease is detailed.
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